Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
DMAC · Why this verdict
Why DiaMedica Therapeutics (DMAC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
DiaMedica is a speculative pre-revenue biotech with a breakout chart and 51.1% upside to the analyst target, but it depends on a single drug candidate and burns cash.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline depends on DM199 and on contract manufacturers, with 3 HIGH concentration risks flagged in the annual report. Bear case | DM199 advances through its next milestones during the next four quarters without a setback. | →Stable |
| CounterA single lead asset is typical of a small biotech and is the source of its upside if trial results are positive. | ||
At $8.72 the stock has 51.1% upside to the $13.17 analyst target against 13.6% downside to the $8.11 stop, a reward-to-risk of 3.74. Upside pct | Price moves toward the analyst target while holding above the stop. | →Stable |
| CounterOnly 4 analysts cover the stock, which dampens the signal, and the target depends on a binary clinical outcome. | ||
Free cash flow is negative, the company has no moat and quality scores 1.7/10, below a 4.0 minimum. Quality breakdown | Quality improves as the pipeline progresses and spending becomes better funded. | →Stable |
| CounterDebt levels are conservative and institutions are accumulating, so the cash burn may be well funded. | ||
A golden cross with the price above all moving averages and momentum scored 6.1/10 supports a breakout setup, with positive news sentiment of +0.60. Chart pattern detection | Price holds above its moving averages and momentum stays above 5.5. | →Stable |
| CounterThe 200-day average slope is flat and the technical score is only 3.1/10, so the breakout may not be confirmed. | ||
Short interest is 15% and implied volatility is 123%, showing the market sees large two-way risk around the clinical outcome. Risk breakdown | Short interest declines as clinical data arrives. | →Stable |
| CounterA put/call ratio of 0.091 shows options traders are positioned bullishly, which could lead to a sharp move on good news. | ||
The pipeline depends on DM199 and on contract manufacturers, with 3 HIGH concentration risks flagged in the annual report.
→StableBear case
- Expectation
- DM199 advances through its next milestones during the next four quarters without a setback.
CounterA single lead asset is typical of a small biotech and is the source of its upside if trial results are positive.
At $8.72 the stock has 51.1% upside to the $13.17 analyst target against 13.6% downside to the $8.11 stop, a reward-to-risk of 3.74.
→StableUpside pct
- Expectation
- Price moves toward the analyst target while holding above the stop.
CounterOnly 4 analysts cover the stock, which dampens the signal, and the target depends on a binary clinical outcome.
Free cash flow is negative, the company has no moat and quality scores 1.7/10, below a 4.0 minimum.
→StableQuality breakdown
- Expectation
- Quality improves as the pipeline progresses and spending becomes better funded.
CounterDebt levels are conservative and institutions are accumulating, so the cash burn may be well funded.
A golden cross with the price above all moving averages and momentum scored 6.1/10 supports a breakout setup, with positive news sentiment of +0.60.
→StableChart pattern detection
- Expectation
- Price holds above its moving averages and momentum stays above 5.5.
CounterThe 200-day average slope is flat and the technical score is only 3.1/10, so the breakout may not be confirmed.
Short interest is 15% and implied volatility is 123%, showing the market sees large two-way risk around the clinical outcome.
→StableRisk breakdown
- Expectation
- Short interest declines as clinical data arrives.
CounterA put/call ratio of 0.091 shows options traders are positioned bullishly, which could lead to a sharp move on good news.
Per-dimension breakdown
Quality
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.3 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 8.4 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 10.0 |
| vol acceleration | 8.5 |
- ▸Overbought (RSI 71)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
- ▸Volume surge (2.3x avg) on up move
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 7.1 |
| Price target | 9.7 |
- ▸LLM news sentiment: +0.50 (n=1)
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 58%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.2 |
| 52w position | 8.8 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.8 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 7.5 |
| debt equity | 10.0 |
- ▸High IV: 137%
- ▸Above max pain $5
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 2.7 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/2M
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:8.2>=5.5
- ASYMMETRY:2.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
2.28
Upside
+34.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 2.28.
The strongest dimensions are Value at 9.0, Momentum at 8.2, and Sentiment at 8.0; the weakest are Quality at 1.7, Technical at 3.3, and Catalyst at 3.8. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 2.28 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Target Asymmetry
Trip ifShare price falls below the $8.11 stop level.
- P2Single Asset Pipeline Dependence
Trip ifThe pipeline includes more than 1 clinical-stage asset.
- P3Cash Burning Low Quality
Trip ifQuality score rises above 4.0 from the current 1.7.
- P4Breakout Momentum Setup
Trip ifMomentum score falls below 4.5 from the current 6.1.
- P5Short Interest And Volatility
Trip ifShort interest exceeds 25% from the current 15%.